Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA: Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines for Avian Influenza A
NCT07128615Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD4117 and AZD5315 in Influenza A (IAV) (10 arms), sponsored by AstraZeneca. Primary endpoints: Percentage of participants with immediate unsolicited adverse events at 30 minutes, Percentage of participants with injection site and systemic solicited adverse reactions at 7 days and 6 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
AZD4117AZD5315
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT07128615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128615.